Eli Lilly and Company

Medivir Ab

John Michael Morin, Jr

Michael Dean Kinnick

Daniel Jon Sall

Jason Scott Sawyer

Robert Theodore Vasileff

Douglas Wade Beight

Ho-Shen Lin

Robert J Ternansky

Michael Enrico Richett

Matthew Joseph Fisher

Joseph A Jakubowski

Allen D Kline

Anne Marie Happ

Marshall A Skelton

Michael J Martinelli

Theo Schotten

Edward C R Smith

Edward David Mihelich

Rolf Noreen

Michael Lyle Denney

Nicholas J Bach

Richard Waltz Harper

Wolfgang Stenzel

Michael Paal

Kenneth James Ruterbories

Peter Tomas Lind

David A Hall, Deceased

Jolie Anne Bastian

Robert D Dillard

Michael LeRoy Phillips

Nancy June Snyder

Benjamin Alan Anderson

Susan Elizabeth Draheim

Tulio Suarez

Lawrence Joseph Heinz, Ii

James Ronald Gillig

Nancy Kay Harn

Gerd Ruhter

Gary A Hite

Richard Walter Schevitz

John Mcneill McGill, Iii

Yen-Shi Lai

Richard James Loncharich

Robert T Shuman

Philip Arthur Hipskind

Robin D Cooper

Kenneth Allen Savin

Larry W Hertel

David A Hall

James Arthur Nixon

William T Jackson

Michael Alan Robertson

Rolf Nor&eacute;en

Douglas Webb Johnson

Carsten Ott

Jochen Ammenn

William C Vladuchick

Gerd R&uuml;hter

Lawrence John Slieker

John Andrew Buben

John David Jandzinski

Tomas Lind

Peter Thomas Lind

Lynn R Peters

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes

A novel class of tricyclic compounds of the following formula (I) is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

[object Object]

The present invention relates to a melanin concentrating hormone antagonist compound of Formula I: (I) wherein Ar, Ar, Ar, L, Land Q areas defined, or a pharmaceutically acceptable salt, solvate, enantiomer or mixture of diastereomers thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and Related Diseases 

MCH receptor antagonists

A novel class of tricyclic compounds of the following formula (I): (formula I); is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of inflammatory diseases such as septic shock 

Cyclohept[b]indole derivatives

A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

sPLA2 inhibitors

A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLAmediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

Spla2 inhibitors

A novel class of tetracyclic compounds represented by the formula Iwherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

A class of novel substituted pyrrole is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

A class of novel tricyclics is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of conditions such as septic shock.

Substituted tricyclics

A class of novel benzo(b)thiophene is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.

spla2 inhibitors

This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Glycoprotein IIB/IIIA antagonists

This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, benzopyran, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.

Glycoprotein IIb/IIIa antagonists

A class of novel oxime indoles is disclosed together with the use of such compounds for inhibiting sPLA mediated release of fatty acids for treatment of inflammatory diseases such as septic shock.

Oxime amide indole type sPLA2 inhibitors

Growing community of inventors

Brownsburg, IN, United States of America

John Michael Morin, Jr